SN
Santen Pharmaceutical Co., Ltd.
SNPHY · OTC
$11.09 -3.06% (-$0.35)
1M -10.56%
Market Cap ¥574.7B
P/E Ratio 14.61x
Div. Yield 1.95%
ROE 13.63%
Bulios Fair Price
$12.48
12.5% upside
Current Price
$11.09
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SNPHY is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
84 /100
Cheap P/E 14.61x
EV/EBITDA 7.97x
PEG 1.56x
Growth
58 /100
Stable Rev. growth 3.48%
FCF growth 45.73%
Book val. growth 0.48%
Profitability
78 /100
Strong Gross margin 56.10%
Net margin 13.26%
FCF margin 12.19%
Quality
65 /100
Average ROIC 11.16%
ROE 13.63%
Asset turnover 0.72x
Debt
100 /100
Low Debt/Equity 0.10x
Current ratio 2.82x
Net debt/EBITDA -0.71x
Stability
40 /100
Moderate Beta 0.24x
Rev. volatility 4.45%
Profitable years 3
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SNPHY
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Takeshi Ito
Employees
3,968
Headquarters
Kita
Upcoming events
29 SEP
Ex-Dividend
Ex-dividend date
30 NOV
Dividend Payment
Payment date